Afamin and apolipoprotein A-IV: Novel protein markers for ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 4, 2009, Pages 1127-1133

  Dieplinger, Hans ^a,b   Ankerst, Donna Pauler ^c   Burges, Alexander ^d   Lenhard, Miriam ^d   Lingenhel, Arno ^a   Fineder, Linda ^a   Buchner, Hannes ^c,d   Stieber, Petra ^d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Vitateq Biotechnology GmbH   (Austria)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMIN; ALPHA TOCOPHEROL; APOLIPOPROTEIN A4; BINDING PROTEIN; CA 125 ANTIGEN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS A; CA-125 ANTIGEN; CARRIER PROTEINS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENDOMETRIOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 66649093207     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0653     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 2003;88:S152-7.
3. Toki T, Kubota J, Lu X, Nakayama K. Immunohistochemical analysis of CA125, CA19-9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation. Acta Obstet Gynecol Scand 2000;79:771-776
4. Molina R, Filella X, Jo J, Agusti C, Ballesta AM. CA 125 in biological fluids. Int J Biol Markers 1998;13:224-230 (Pubitemid 29178554)
5. Hogdall E. Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008;20:4-8.
6. Wang H, Kachman MT, Schwartz DR, Cho KR, Lubman DM. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers. Proteomics 2004;4:2476-2495 (Pubitemid 39025348)
7. Zhang Z, Bast RC, Jr., Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-5890 (Pubitemid 39095590)
8. Bast RC, Jr., Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15 Suppl 3:274-281 (Pubitemid 43096594)
9. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-3700 (Pubitemid 36793054)
10. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999;96:11531-11536 (Pubitemid 29487415)
11. Xu FJ, Ramakrishnan S, Daly L, et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 1991;165:1356-1362
12. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-1679 (Pubitemid 34289219)
13. Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 1999;73:56-61. (Pubitemid 29177600)
14. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-1072
15. Jackson D, Craven RA, Hutson RC, et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007;13:7370-7379
16. Jerkovic L, Voegele AF, Chwatal S, et al. Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression. J Proteome Res 2005;4:889-899 (Pubitemid 40863278)
17. Lichenstein HS, Lyons DE, Wurfel MM, et al. Afamin is a new member of the albumin, α-fetoprotein, and vitamin D-binding protein gene family. J Biol Chem 1994;269:18149-18154 (Pubitemid 24982656)
18. Voegele AF, Jerkovic L, Wellenzohn B, et al. Characterization of the vitamin E-binding properties of human plasma afamin. Biochemistry 2002;41:14532-14538 (Pubitemid 35440265)
19. Kronenberg F, Stuhlinger M, Trenkwalder E, et al. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol 2000;36:751-757
20. Haiman M, Salvenmoser W, Scheiber K, et al. Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int 2005;68:1130-1136 (Pubitemid 43246429)
21. Lai CQ, Parnell LD, Ordovas JM. The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol 2005;16:153-166 (Pubitemid 40515889)
22. Beisiegel U, Utermann G. An apolipoprotein homology of rat apolipoprotein A-IV in human plasma: isolation and partial characterization. Eur J Biochem 1979;93:601-608 (Pubitemid 9218159)
23. Ezeh B, Haiman M, Alber HF, et al. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res 2003;44:1523-1529 (Pubitemid 37279597)
24. Stan S, Delvin E, Lambert M, Seidman E, Levy E. Apo A-IV: an update on regulation and physiologic functions. Biochim Biophys Acta 2003;1631:177-187 (Pubitemid 36292149)
25. Broedl UC, Schachinger V, Lingenhel A, et al. Apolipoprotein AIV is an independent predictor of disease activity in patients with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:391-397 (Pubitemid 46668243)
26. Boes E, Fliser D, Ritz E, et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2006;17:528-536
27. Dieplinger H, Lobentanz E-M, König P, et al. Plasma apolipoprotein A-IV metabolism in patients with chronic renal disease. Eur J Clin Invest 1992;22:166-174
28. Lingenhel A, Lhotta K, Neyer U, et al. Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria. J Lipid Res 2006;47:2071-2079 (Pubitemid 44401996)
29. Sobin LH, Wittekind C. International Union against Cancer (UICC). TNM classification of malignant tumors. 6th ed. New York (NY): Wiley-Liss; 2002.
30. Rafat M, Sattler AM, Hackler R, et al. Apolipoprotein A-IV in the fed and fasting states. Clin Chem 2004;50:1270-1271 (Pubitemid 38824248)
31. Kronenberg F, Lobentanz E-M, König P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res 1994;35:1318-1328 (Pubitemid 2110236)
32. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845 (Pubitemid 18243017)
33. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
34. Bast RC, Jr., Brewer M, Zou C, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 2007;174:91-100.